HHLR Advisors’s LakeShore Biopharma LSB Stock Holding History

HHLR Advisors’s Portfolio LSB Stock Details LSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-75,179	Closed	-$76.7K	–	41
2025 Q2	$76.7K	Hold	75,179	–	–	﹤0.01%	34
2025 Q1	$182K	Hold	75,179	–	–	0.01%	47
2024 Q4	$259K	Hold	75,179	–	–	0.01%	43
2024 Q3	$513K	Hold	75,179	–	–	0.01%	45
2024 Q2	$487K	Hold	75,179	–	–	0.01%	74
2024 Q1	$526K	Hold	75,179	–	–	0.01%	58
2023 Q4	$404K	Hold	75,179	–	–	0.01%	47
2023 Q3	$601K	Hold	75,179	–	–	0.01%	56
2023 Q2	$1.04M	Hold	75,179	–	–	0.02%	53
2023 Q1	$1.2M	Buy	+75,179	New	+$3.81M	0.02%	66

Other funds holding LSB

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

HHLR Advisors's LSB Position: Q3 2025 in Review

HHLR Advisors sold out of LakeShore Biopharma (LSB) in Q3 2025, closing a stake of 75,179 shares — an estimated $76.7K sold.

HHLR Advisors first reported a position in LSB in Q1 2023 and held it in 10 quarters. The position peaked at $1.2M in Q1 2023. 1 fund tracked by Wall St. Rank holds LSB as of Q3 2025.

HHLR Advisors reported no remaining LakeShore Biopharma position as of Q3 2025 after selling out during the quarter.
HHLR Advisors sold 75,179 LakeShore Biopharma shares in Q3 2025, an estimated $76.7K.
HHLR Advisors first reported a position in LakeShore Biopharma in Q1 2023 and held it in 10 quarters.
HHLR Advisors's LakeShore Biopharma position peaked at $1.2M in Q1 2023.
1 fund tracked by Wall St. Rank held LakeShore Biopharma as of Q3 2025.

Based on HHLR Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.